Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group.
about
Mepolizumab versus placebo for asthmaOmalizumab for asthma in adults and childrenAnti-IgE for chronic asthma in adults and childrenAnti-IgE for chronic asthma in adults and childrenAntibodies specific for a segment of human membrane IgE deplete IgE-producing B cells in humanized miceWhat have transgenic and knockout animals taught us about respiratory disease?Environmental contributions to the allergic asthma epidemic.Conformational Flexibility in Immunoglobulin E-Fc3–4 Revealed in Multiple Crystal FormsBiomarkers of patient intrinsic risk for upper and lower airway injury after exposure to the World Trade Center atrocityThe pharmacological basis of anti-IgE therapyCorticosteroids, IgE, and atopyNon-eosinophilic asthma: importance and possible mechanismsTargeting patients with asthma for omalizumab therapy: choosing the right patient to get the best value for money.The role of allergy in severe asthma.Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin.The role of omalizumab in the treatment of severe allergic asthma.Evolving Concepts of Asthma.Omalizumab in Severe Refractory Vernal Keratoconjunctivitis in Children: Case Series and Review of the Literature.Reduced FcepsilonRI-mediated release of asthma-promoting cytokines and chemokines from human basophils during omalizumab therapy.The Role of Type 2 Inflammation in the Pathogenesis of Asthma Exacerbations.Recent advances: Respiratory medicine.Elicitation of allergic asthma by immunoglobulin free light chainsAccelerated dissociation of IgE-FcεRI complexes by disruptive inhibitors actively desensitizes allergic effector cells.Suppression of IgE B cells and IgE binding to Fc(epsilon)RI by gene therapy with single-chain anti-IgE.Immunotherapy in food allergy.Omalizumab: the evidence for its place in the treatment of allergic asthmaIgE actions on CD4+ T cells, mast cells, and macrophages participate in the pathogenesis of experimental abdominal aortic aneurysms.Chronic allergen challenge induces bronchial mast cell accumulation in BALB/c but not C57BL/6 mice and is independent of IL-9.Biotherapeutic targets for the treatment of allergic airway disease.Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders.Airway remodelling in asthma: from benchside to clinical practice.Drug treatment of airway inflammation in asthma.What are the most promising strategies for the therapeutic immunomodulation of allergic diseases?Classic specific immunotherapy and new perspectives in specific immunotherapy for food allergy.Leukotriene inhibitors and non-steroidal therapies in the treatment of asthma.How to manage difficult asthma cases. An action plan for physicians and patients.Children with difficult asthma: a practical approach.Application of quantitative pharmacology in development of therapeutic monoclonal antibodiesTreatment strategies for bronchial asthma: an update.Severe asthma: definition and mechanisms.
P2860
Q24186306-0ED4E365-7FDF-4C3B-AA27-220C7C46C92FQ24201145-06CF4E99-51BA-42F6-BD8A-9BE883E56EADQ24246484-012E8E10-624C-4116-91E7-A0934357B941Q24247152-6820C86B-E05E-4F51-A9A4-CE9DEB33063DQ24604440-C1D07307-284D-4085-B4DE-177C1A19A41EQ24791345-AFB6A029-655D-410F-B563-84B3612BB4EDQ24812202-B299221B-3796-47A2-8ECB-2716F6A4B8E5Q27657021-DAB28385-29F3-42CD-83B0-E950A094A4CCQ27908435-7A5B9A4F-2DA7-4823-BFFC-E4ED2FA87B12Q28143946-7262F626-85AF-42EE-9213-2C2E942F7334Q28346545-41D319EA-260E-41DF-B999-1BCA881089EBQ28394141-E2B04E88-24F7-499D-A468-04F98DCC98EFQ30360362-D65496BB-3966-4DB9-A7F0-C9982E0D9F2DQ30419500-C8B2B58C-9DC9-4700-8AD9-9615E82E8325Q33588223-7380A4DD-4666-4914-AA65-188C91B604FAQ33591890-9E2357D4-C6ED-4A09-BE3F-1B1CE8FA44D3Q33735605-07D3D851-729E-4A04-9586-409870F0371EQ33740109-BB495FA9-115F-4883-8313-8BDE8CBBEB62Q33785112-F2874C41-68C9-4291-981D-968EB5888710Q33786076-DF83489B-8205-42EC-8D1E-413F2248E54EQ33808282-535B5848-75C8-48B2-8DAA-97D68527394BQ33817653-20F1C71A-B707-4948-96D7-30E233193B04Q33850604-B8E17795-A6BF-4255-8DA6-028B4C840D31Q33870977-48CED1C0-0BB2-4914-91F6-537EC518FF26Q33899364-8C4FE3BD-FAD9-4AEF-BB68-BC0B0BEDC69DQ33973970-E54E0135-9147-4286-BA2B-ED60F9606520Q33991483-917A2C7C-F4E4-4452-A896-A35A934178DDQ34021220-E5152214-68BB-4FA1-9E66-B4E0690F5A6FQ34058685-07345EF8-4FAC-4106-963B-FF85054C9D31Q34101369-180AAF97-342C-415E-8F14-E6175FBE3335Q34105688-01399A9A-64E1-4B84-AF9F-867E7E464A25Q34186818-156149EA-48FA-4C64-A2EB-0AEFD865B566Q34190563-C4A85C5C-1241-4385-B0DB-3045E9F7E626Q34216109-3E823CFD-8E4C-4F27-8B7F-375B0FFA0255Q34240729-3209E526-2E83-4EC3-A8A4-D9235DD8CC03Q34267156-3FC988CD-4FCF-4DA8-9579-D43246ECF5E4Q34273468-619461A2-5710-4030-B570-375BDCAEBA8AQ34293689-0523784B-E6AF-4926-B5C1-1BBCA43C7D1BQ34342572-424DA8F5-3E6A-4422-97D4-2B826C8FE9E2Q34364866-520C6890-DBA9-4E54-9B9D-1AA24CD4C25C
P2860
Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group.
@en
Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group.
@nl
type
label
Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group.
@en
Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group.
@nl
prefLabel
Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group.
@en
Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group.
@nl
P2093
P1476
Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group.
@en
P2093
Fick RB Jr
Metzger WJ
Reimann JD
Watrous ML
P304
P356
10.1056/NEJM199912233412603
P407
P577
1999-12-01T00:00:00Z